What Investors Got Wrong About Aurora Cannabis Before The Drop

Curaleaf’s hostile bid for Aurora Cannabis and the board’s pushback made headlines, then a fresh quarter showed revenue lower than a year earlier while the loss narrowed and net margin improved. Holding Aurora Cannabis over the past year would have meant a 25.6% loss, including dividends. If you had bought on 23 October 2025, that mix of takeover noise and mixed Q1 2027 figures now raises a sharper question: Did the earlier optimism about international medical markets leave too much to prove?

If the move has made Aurora Cannabis harder to judge, start where the gap is still open and scan 3 high quality undervalued stocks.

The Two Futures Investors Were Arguing About For Aurora Cannabis

The shares cost CA$7.11 at the start of the period, and the live question for Aurora Cannabis was how far international medical markets could really take the business.

The bullish story pointed to a Fair Value of CA$7.92. That price was implied by assumptions like 5.3% annual revenue growth and profit margins rising toward 10.1% as European and Australian medical sales scaled up.

The bearish view anchored on a Fair Value of CA$6, with worries that tight cannabis regulations and competition would hold profit margins near 1.2% and require a lofty 87.7x future P/E to justify that outcome.

What The Results Changed For Aurora Cannabis

The key fresh data point for Aurora Cannabis was Q1 2027, when revenue slipped to CA$67.6m from CA$74.1m a year earlier, while the loss narrowed from CA$10.2m to CA$4.0m and net margin improved from -13.8% to -6.0%. That pattern partly backed the cautious case on top-line momentum but left the bullish profitability story still unproven because earnings remained negative.

The useful takeaway is about which promise you trust. When a thesis leans on future high-margin markets, keep checking whether net margin and absolute profit are turning, and not just whether management talks up international opportunity.

What Aurora Cannabis Buyers Are Really Paying For Today

Aurora Cannabis now trades at CA$5.46, after the shares fell 25.6% over the past year. The selected Narrative sees a Fair Value above that level, based on a stronger role for higher margin international medical sales and EU GMP certified capacity.

On that view, a buyer today is effectively assuming Aurora Cannabis can shift its revenue mix toward international medical cannabis quickly enough, and at attractive margins, to offset pressure on Canadian earnings.

"Key Takeaways: Bullish analysts expect Aurora Cannabis to translate its focus on higher margin global medical cannabis and expanding EU GMP certified capacity into faster growth and a stronger competitive position in key international markets. The main thing that has to go right is that Aurora Cannabis continues to shift its revenue mix toward international medical cannabis quickly enough, and at attractive margins, to more than offset pressure from lower Canadian medical reimbursement and related earnings volatility."

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there

Another Way To Play Medical Demand

Aurora Cannabis is trying to lean harder into medical use. You could also look one step away from cannabis entirely.

Healthcare systems need more than new therapies. They also need devices, procedures and diagnostics that make treatments usable at scale.

One large global supplier focuses on medicines and equipment for complex diseases. It devotes significant resources to research and deal making to keep that engine running.

Its drugs address difficult problems in cancer, immune disorders and brain health. Surgical and vision products aim to make complex procedures more precise and efficient.

If medical demand keeps shifting toward specialist care, that kind of toolkit could become increasingly important.

One Narrative has already put a figure on it. → Uncover the company trading 18% below one Narrative's Fair Value

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com